Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
100%(11 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
7
58%
Ph phase_2
4
33%
Ph phase_3
1
8%

Phase Distribution

7

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
7(58.3%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
91.7%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (58.3%)
Phase 24 (33.3%)
Phase 31 (8.3%)

Trials by Status

completed1192%
terminated18%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_1

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

NCT01126749
completedphase_3

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00388726
completedphase_2

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

NCT00413192
completedphase_1

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

NCT01432886
completedphase_1

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

NCT01418677
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01126749Phase 1

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Terminated
NCT00388726Phase 3

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
NCT00413192Phase 2

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Completed
NCT01432886Phase 1

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Completed
NCT01418677Phase 1

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Completed
NCT00278993Phase 2

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Completed
NCT00246090Phase 2

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Completed
NCT00097721Phase 2

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Completed
NCT00069277Phase 1

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

Completed
NCT00706095Phase 1

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Completed
NCT00326950Phase 1

Phase I Clinical Study of E7389

Completed
NCT00069264Phase 1

Study of E7389 in Patients With Advanced Solid Tumors

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12